1.Julian BA, Waldo FB, Rifai A, Mestecky J: IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? The American journal of medicine 1988, 84(1):129–32.
2.D’Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. The Quarterly journal of medicine 1987, 64(245):709–27.
3.Yeo SC, Cheung CK, Barratt J: New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol 2017. doi:10.1007/s00467–017–3699-z
4.Barratt J, Feehally J: IgA nephropathy. Journal of the American Society of Nephrology: JASN 2005, 16(7):2088–97. doi:10.1681/asn.2005020134
5.Coppo R, D’Amico G: Factors predicting progression of IgA nephropathies. Journal of nephrology 2005, 18(5):503–12.
6.Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y: A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2009, 24(10):3068–74. doi:10.1093/ndt/gfp273
7.Berger J, Hinglais N: [Intercapillary deposits of IgA-IgG]. Journal d’urologie et de nephrologie 1968, 74(9):694–5.
8.Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA et al: Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. The Journal of clinical investigation 2009, 119(6):1668–77. doi:10.1172/jci38468
9.Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C et al: Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. Journal of the American Society of Nephrology: JASN 2012, 23(9):1579–87. doi:10.1681/asn.2012010053
10.Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K et al: A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PloS one 2014, 9(5):e98081. doi:10.1371/journal.pone.0098081
11.Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N et al: Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clinical and experimental nephrology 2014, 18(5):770–7. doi:10.1007/s10157–013–0921–6
12.Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Drame M et al: Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney international 2015. doi:10.1038/ki.2015.158
13.Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB et al: The pathophysiology of IgA nephropathy. Journal of the American Society of Nephrology: JASN 2011, 22(10):1795–803. doi:10.1681/asn.2011050464
14.Giannakakis K, Feriozzi S, Perez M, Faraggiana T, Muda AO: Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. Journal of the American Society of Nephrology: JASN 2007, 18(12):3139–46. doi:10.1681/asn.2007030259
15.Komatsu N, Nagura H, Watanabe K, Nomoto Y, Kobayashi K: Mesangial deposition of J chain-linked polymeric IgA in IgA nephropathy. Nephron 1983, 33(1):61–4.
16.Donini U, Casanova S, Zini N, Zucchelli P: The presence of J chain in mesangial immune deposits of IgA nephropathy. Proceedings of the European Dialysis and Transplant Association European Dialysis and Transplant Association 1983, 19:655–62.
17.Oortwijn BD, Rastaldi MP, Roos A, Mattinzoli D, Daha MR, van Kooten C: Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2007, 22(11):3191–5. doi:10.1093/ndt/gfm346
18.Brandtzaeg P: Presence of J chain in human immunocytes containing various immunoglobulin classes. Nature 1974, 252(5482):418–20.
19.Brandtzaeg P: Immunochemical studies on free and bound J chain of human IgA and IgM. Scandinavian journal of immunology 1975, 4(5–6):439–50.
20.Castro CD, Flajnik MF: Putting J chain back on the map: how might its expression define plasma cell development? Journal of immunology 2014, 193(7):3248–55. doi:10.4049/jimmunol.1400531
21.Lozano L, Garcia-Hoyo R, Egido J: IgA nephropathy: association of a history of macroscopic hematuria episodes with increased production of polymeric IgA. Nephron 1987, 45(2):98–103. doi:10.1159/000184087
22.Jones CL, Powell HR, Kincaid-Smith P, Roberton DM: Polymeric IgA and immune complex concentrations in IgA-related renal disease. Kidney international 1990, 38(2):323–31. doi:10.1038/ki.1990.204
23.Trascasa ML, Egido J, Sancho J, Hernando L: IgA glomerulonephritis (Berger’s disease): evidence of high serum levels of polymeric IgA. Clinical and experimental immunology 1980, 42(2):247–54.
24.Zhang JJ, Xu LX, Liu G, Zhao MH, Wang HY: The level of serum secretory IgA of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2008, 23(1):207–12. doi:10.1093/ndt/gfm492
25.Bene MC, Faure G, Duheille J: IgA nephropathy: characterization of the polymeric nature of mesangial deposits by in vitro binding of free secretory component. Clinical and experimental immunology 1982, 47(3):527–34.
26.Lai KN, Tang SC, Guh JY, Chuang TD, Lam MF, Chan LY et al: Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. Journal of the American Society of Nephrology: JASN 2003, 14(12):3127–37.
27.Leung JC, Tang SC, Chan LY, Tsang AW, Lan HY, Lai KN: Polymeric IgA increases the synthesis of macrophage migration inhibitory factor by human mesangial cells in IgA nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2003, 18(1):36–45.
28.van Dixhoorn MG, Sato T, Muizert Y, van Gijlswijk-Janssen DJ, De Heer E, Daha MR: Combined glomerular deposition of polymeric rat IgA and IgG aggravates renal inflammation. Kidney international 2000, 58(1):90–9. doi:10.1046/j.1523–1755.2000.00144.x
29.van den Dobbelsteen ME, van der Woude FJ, Schroeijers WE, van den Wall Bake AW, van Es LA, Daha MR: Binding of dimeric and polymeric IgA to rat renal mesangial cells enhances the release of interleukin 6. Kidney international 1994, 46(2):512–9.
30.Matousovic K, Novak J, Yanagihara T, Tomana M, Moldoveanu Z, Kulhavy R et al: IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2006, 21(9):2478–84. doi:10.1093/ndt/gfl240
31.Wang J, Xie P, Huang JM, Qu Y, Zhang F, Wei LG et al: The new Asian modified CKD-EPI equation leads to more accurate GFR estimation in Chinese patients with CKD. International urology and nephrology 2016, 48(12):2077–81. doi:10.1007/s11255–016–1386–9
32.Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M et al: Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 2017, 91(5):1014–21. doi:10.1016/j.kint.2017.02.003
33.Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH et al: IgA nephropathy: morphologic predictors of progressive renal disease. Human pathology 1982, 13(4):314–22.
34.Novak J, Vu HL, Novak L, Julian BA, Mestecky J, Tomana M: Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney international 2002, 62(2):465–75. doi:10.1046/j.1523–1755.2002.00477.x
35.Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L et al: IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney international 2005, 67(2):504–13. doi:10.1111/j.1523–1755.2005.67107.x
36.Novak J, Moldoveanu Z, Renfrow MB, Yanagihara T, Suzuki H, Raska M et al: IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contributions to nephrology 2007, 157:134–8. doi:10.1159/0000102455
37.Valentijn RM, Radl J, Haaijman JJ, Vermeer BJ, Weening JJ, Kauffmann RH et al: Circulating and mesangial secretory component-binding IgA–1 in primary IgA nephropathy. Kidney international 1984, 26(5):760–6.
38.Brandtzaeg P, Farstad IN, Johansen FE, Morton HC, Norderhaug IN, Yamanaka T: The B-cell system of human mucosae and exocrine glands. Immunological reviews 1999, 171:45–87.
39.Brandtzaeg P, Prydz H: Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 1984, 311(5981):71–3.
40.Brandtzaeg P: Transport models for secretory IgA and secretory IgM. Clinical and experimental immunology 1981, 44(2):221–32.
41.Hossain N, Khan N, Shah N, Shah T, Butt S, Khanani R: Spot urine protein-creatinine ratio and 24-h urine protein excretion: Diagnostic accuracy in women with pre-eclampsia. Pregnancy hypertension 2014, 4(1):87–90. doi:10.1016/j.preghy.2013.11.007
42.Lane C, Brown M, Dunsmuir W, Kelly J, Mangos G: Can spot urine protein/creatinine ratio replace 24 h urine protein in usual clinical nephrology? Nephrology 2006, 11(3):245–9. doi:10.1111/j.1440–1797.2006.00564.x